Author:
Nguyen L.,Leger F.,Lennon S.,Puozzo C.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference34 articles.
1. Andersson BS, Kashyap A, Gian V et al (2002) Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 8:145–154
2. Andersson BS, Thall PF, Madden T et al (2002) Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for IV BuCy2 in chronic myelogenous leukaemia. Biol Blood Marrow Transplant 8:477–485
3. Beal SL, Sheiner LB (1998) NONMEM user’s guide. University of California, San Francisco
4. Bostrom B, Enockson K, Johnson A et al (2003) Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation. Pediatr Transplant 7(suppl 3):12–18
5. Buggia I, Zecca M, Alessandrino EP et al (1996) Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. Anticancer Res 16:2083–2088
Cited by
94 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献